Q&A: Can on­colyt­ic virus­es make a come­back? Ex­perts dis­sect clin­i­cal fail­ures and out­line path for­ward

In the eight years since the FDA first ap­proved an on­colyt­ic virus as a can­cer ther­a­py, de­vel­op­ers have been striv­ing — and large­ly fail­ing — to bring next-gen treat­ments to the mar­ket. But a new wave could be up­on us.

Can on­colyt­ic virus­es make a come­back? That was a top­ic of a re­cent pan­el host­ed by End­points News. Our guests were Paul Pe­ter Tak, a for­mer GSK ex­ec who’s now CEO of vi­ral im­munother­a­py de­vel­op­er Can­del Ther­a­peu­tics; Howard Kauf­man, the pres­i­dent and CEO of Ankyra Ther­a­peu­tics and a long­time re­searcher of on­colyt­ic virus­es; and Ad­i­na Pelu­sio, the se­nior vice pres­i­dent of clin­i­cal op­er­a­tions at KaliVir Im­munother­a­peu­tics, who has more than 20 years of ex­pe­ri­ence lead­ing clin­i­cal tri­als for these ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER